Scholars@Duke

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Publication ,  Journal Article
Zelenetz, AD; Gordon, LI; Abramson, JS; Advani, RH; Andreadis, B; Bartlett, NL; Budde, LE; Caimi, PF; Chang, JE; Christian, B; DeVos, S; Hu, B ...
Published in: J Natl Compr Canc Netw
October 2025
Published version (DOI) Link to item

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.

Duke Scholars

Christopher Ryan Kelsey
Author Christopher Ryan Kelsey Radiation Oncology

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2025.0048

EISSN

1540-1413

Publication Date

October 2025

Volume

23

Issue

10

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., … Sundar, H. (2025). NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw, 23(10). https://doi.org/10.6004/jnccn.2025.0048
Zelenetz, Andrew D., Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L Elizabeth Budde, et al. “NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.” J Natl Compr Canc Netw 23, no. 10 (October 2025). https://doi.org/10.6004/jnccn.2025.0048.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw. 2025 Oct;23(10).
Zelenetz, Andrew D., et al. “NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.” J Natl Compr Canc Netw, vol. 23, no. 10, Oct. 2025. Pubmed, doi:10.6004/jnccn.2025.0048.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Saito NG, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw. 2025 Oct;23(10).

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2025.0048

EISSN

1540-1413

Publication Date

October 2025

Volume

23

Issue

10

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis